The Native Antigen Co., finds China distribution partner

UK-based The Native Antigen Company, a leading supplier of specialist reagents, will be venturing into the China market after signing up Shanghai Bioleaf to act as distribution partner for the market. That came alongside a separate deal with Germany-based BIOZOL, which will distribute the firm’s products in Germany, Switzerland, and Austria. No financial specifics to either deal were disclosed.

The Oxford-based The Native Antigen Company creates specialized reagents based on isolating and purifying native antigens and recombinant proteins from viral and bacterial pathogens in mammalian cell expression systems. Its products are used by pharmaceutical, in vitro diagnostic (IVD) assay manufacturers and academic institutes carrying out research and serology for vaccines.


Related news
Canada-based SemaThera Inc., announced the closing of a USD 2 million co-investment from Japan’s Senju Pharmaceutical Co., Ltd. and AmorChem L.P. for the development of its lead candidate, ST-102, in preparation for a clinical trial application in diabetic macular edema (DME).
U.S.-based biotech TCR2 Therapeutics announced a successful Series B financing round had raised USD 125 million.
China-based Shandong Weigao Group Medical Polymer Co., Ltd, announced that it has closed the acquisition of U.S.-based firm Argon Medical Devices Inc., for an adjusted price of USD 844.2 million.
Canada-based biotech Oncolytics signed a licensing deal with Chinese biotech Adlai Nortye, focused on development of the former’s proprietary immuno-oncolytic virus Reolysin.
China-based Shandong Weigao Group Medical Polymer Co., Ltd has sealed a deal to purchase the U.S.-based firm Argon Medical Devices Inc., for a price of USD 850 million, according to a statement to the Hong Kong Stock Exchange.
Recent news
The Brazil-based Institute of Technology and Pharmaceuticals (Farmanguinhos), the drug making unit of the Oswaldo Cruz Foundation (Fiocruz), has delivered its pilot batches of hyperprolactinemia (HPRL) treatment cabergoline, the result of a Productive Development Partnership (PDP) with compatriot laboratory Cristália that concluded this year.
Brazil’s National Health Surveillance Agency (ANVISA) this week granted registration approval to Eli Lilly’s biologic drug Emgality (galcanezumab-gnlm), as revealed by GBI analysis.
The new Science and Technology Innovation Board (STAR) hosted by the Shanghai Stock Exchange (SSE) opened for business on July 22.
Belgium-based UCB announced the market approval in China for Cimzia (certolizumab pegol), for the indication of moderate-to-severe rheumatoid arthritis (RA).
  • 1563867876525
  • China
  • Drug
Denmark-based diabetes specialist Novo Nordisk has invested MXN 400 million (USD 21 million) in clinical research in Mexico between 2014 and 2018, involving 1,200 patients in 21 trials.
The Shandong Centralized Drug Procurement platform released a notification in relation to public hospital drug and consumables procurement alliances.
The “4+7” volume-linked drug procurement pilot scheme introduced at the end of 2018 in 11 cities is set to be expanded to all regions of the country, following a meeting between the National Health Security Administration (NHSA) and industry stakeholders held last week.
  • 1563857070043
  • China
Analytics Snapshot

Analytics Snapshot